# Regeneron

Type: Company (REGN)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/regeneron
Canonical HTML page: https://gethealthbrief.com/entity/regeneron

## Recent coverage (1 stories)

### New pill cuts LDL 59%: How Lipfendra could change cholesterol care for millions
2026-07-16 22:00:46 · Sentiment: Very Bullish · Impact: 9/10 · Sources: 132

The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol.
Full story: https://gethealthbrief.com/story/lipfendra-oral-pcsk9-lowers-ldl-59-percent-patient-access

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.